The Division of Experimental Hematology formed part of a multi-center consortium that successfully applied for a three year funding program from the DFG, to study aging-associated epigenetic as a therapeutic target in acute myeloid leukemia. The Division’s role in the Forschergruppe will be to investigate epigenetic remodelling and clonal selection in a murine model of accelerated hematopoietic stem cell aging, and will be carried out in collaboration with Dr. Daniel Lipka from the Divison of Epigenomics and Cancer Risk Factors.